← Leaderboards
Chung K Chu
University Of Georgia (Uga)
$7,118,357
Attributed
$7,118,357
Total exposure
5
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $728.3K · FY2005–10$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$7,118,357 · 5
By mechanism
R37$4,445,303 · 1
R01$2,344,536 · 3
U01$328,518 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Drug Design /Synthesis /Production”
- Dennis L. Kasper · Harvard Medical School$26,605,444
- Myron Max Levine · University Of Maryland Baltimore$22,074,862
- George R Painter · Chimerix, Inc.$19,230,662
- Donald L Fine · Dynport Vaccine Company, Llc$9,996,228
- Dennis E. Hruby · Oregon State University$9,654,233
- William C Olson · Progenics Pharmaceuticals, Inc.$8,361,679
Research focus
Drug Design /Synthesis /ProductionHuman Immunodeficiency VirusPharmacokineticsAntiaids AgentNucleoside AnalogDrug ResistanceMacaca MulattaProdrugsTissue /Cell CultureAntiviral AgentsDrug Screening /EvaluationLaboratory Mouse2'3'DideoxynucleosideAdenosine DeaminaseStereochemistryAids TherapyLaboratory RatAidsDrug InteractionsConformationNucleic Acid Chemical SynthesisBiotransformationAnti-Hiv AgentsAnimal Model
Grant awards (21)
Synthesis and Biotransformation of Anti-HIV Prodrugs$521,693
R37 · FY2010 · AI · contact PI
Synthesis and Biotransformation of Anti-HIV Prodrugs$511,613
R37 · FY2009 · AI · contact PI
Synthesis and Biotransformation of Anti-HIV Prodrugs$496,711
R37 · FY2008 · AI · contact PI
Synthesis and Biotransformation of Anti-HIV Prodrugs$491,584
R37 · FY2007 · AI · contact PI
Synthesis and Biotransformation of Anti-HIV Prodrugs$503,323
R37 · FY2006 · AI · contact PI
Synthesis and Biotransformation of Anti-HIV Prodrugs$405,867
R37 · FY2005 · AI
Synthesis/Biological evaluation of Anti-HIV Nucleosides$322,455
R01 · FY2005 · AI
Synthesis and Biotransformation of Anti-HIV Prodrugs$394,042
R37 · FY2004 · AI
Synthesis/Biological evaluation of Anti-HIV Nucleosides$313,063
R01 · FY2004 · AI
Synthesis and Biotransformation of Anti-HIV Prodrugs$382,566
R37 · FY2003 · AI
Synthesis/Biological evaluation of Anti-HIV Nucleosides$303,947
R01 · FY2003 · AI
Synthesis and Biotransformation of Anti-HIV Prodrugs$371,422
R37 · FY2002 · AI
Synthesis/Biological evaluation of Anti-HIV Nucleosides$306,294
R01 · FY2002 · AI
Nucleoside &cidofovir analogs as pox virus antiviral$109,506
U01 · FY2002 · AI
Synthesis and Biotransformation of Anti-HIV Prodrugs$366,482
R37 · FY2001 · AI
SYNTHESIS AND BIOLOGICAL EVALUATION/ANTIHIV NUCLEOSIDES$241,696
R01 · FY2001 · AI
Nucleoside &cidofovir analogs as pox virus antiviral$109,506
U01 · FY2001 · AI
SYNTHESIS AND BIOTRANSFORMATION OF ANTIHIV PRODRUGS$353,514
R01 · FY2000 · AI
ASYMMETRIC SYNTHESIS OF L-NUCLEOSIDES AS ANTI-HBV AGENTS$268,669
R01 · FY2000 · AI
SYNTHESIS AND BIOLOGICAL EVALUATION/ANTIHIV NUCLEOSIDES$234,898
R01 · FY2000 · AI
Nucleoside &cidofovir analogs as pox virus antiviral$109,506
U01 · FY2000 · AI